ArticleImmunology2004
Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils.
Article in Immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 260 citations in OpenAlex.
- Evaluation of cutaneous immune response in a controlled human in vivo model of mosquito bites.Nature communications · 2022Trial
- Article
- Mechanistic Insights into Human Defensin Antimicrobial Activity from Membrane Simulations.The Journal of membrane biology · 2026Article
- Evaluation of Biological Effect ofAdvances in pharmacological and pharmaceutical sciences · 2026Article
- HPV16 E7 inhibits HBD2 expression by down-regulation of ASK1-p38 MAPK pathway in cervical cancer.Virology journal · 2025Article
- Mast cell activators as adjuvants for intranasal mucosal vaccines.International journal of pharmaceutics · 2025Review
- Assesment of Salivary and Serum Levels of HBD2 in Patients with Chronic Angioedema.Journal of clinical medicine · 2024Article
- Possible immunomodulatory role of Filifactor alocis through beta-defensin 2 in gingival keratinocytes.Clinical oral investigations · 2024Article
- Role of innate host defense proteins in oral cancerogenesis.Periodontology 2000 · 2024Review
- Roles of airway and intestinal epithelia in responding to pathogens and maintaining tissue homeostasis.Frontiers in cellular and infection microbiology · 2024Review
- Mechanisms and regulation of defensins in host defense.Signal transduction and targeted therapy · 2023Review
- The Serum Level of CXCL9, CXCL10, and CXCL11 and the Expression of CXCR3 of Peripheral Blood Mononuclear Cells in Brucellosis Patients.Current microbiology · 2023Article
- Low human beta-defensin-2 levels in the sputum of COPD patients are associated with the risk of exacerbations.BMC pulmonary medicine · 2023Article
- Defensins: defenders of human reproductive health.Human reproduction update · 2023Review
- Etiopathogenesis of Psoriasis from Genetic Perspective: An updated Review.Current genomics · 2022Review
- Psoriasis: An Immunogenetic Perspective.Global medical genetics · 2022Review
- Frontiers in Lichen Planopilaris and Frontal Fibrosing Alopecia Research: Pathobiology Progress and Translational Horizons.JID innovations : skin science from molecules to population health · 2022Review
- Immunomodulatory and Allergenic Properties of Antimicrobial Peptides.International journal of molecular sciences · 2022Review
- Human β-Defensin 2 (HBD-2) Displays Oncolytic Activity but Does Not Affect Tumour Cell Migration.Biomolecules · 2022Article
- Antimicrobial Peptide Expression at the Ocular Surface and Their Therapeutic Use in the Treatment of Microbial Keratitis.Frontiers in microbiology · 2022Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils are the effector cells in both innate and adaptive immunity, where they perform the functions of phagocytosis and killing of bacteria. They respond to a large number of chemoattractants, but their response to epithelial cell-derived human beta-defensins (hBD) has not been investigated. Here we report that hBD-2, but not hBD-1, is a specific chemoattractant for tumour necrosis factor (TNF)-alpha-treated human neutrophils. The optimal concentration required for maximal chemotactic activity was 5 micro g/ml. The effect of hBD-2 on neutrophils was dependent on the G-protein-phospholipase C pathway, as demonstrated by inhibition by pertussis toxin and U-73122. In addition, ligand-receptor analysis indicated that the binding of hBD-2 was markedly inhibited by macrophage inflammatory protein (MIP)-3alpha, a specific and unique ligand for CCR6. Furthermore, anti-CCR6 antibody could almost completely suppress the cell migration induced by hBD-2, suggesting that hBD-2 mainly utilizes CCR6 as a functional receptor. Thus, our finding that hBD-2 is a potent chemoattractant for human neutrophils through specific receptors provides a novel mechanism by which this peptide contributes to the host defence system by recruiting neutrophils to inflammation/infection sites. This also suggests an important link between epithelial cell-derived antibacterial peptides and neutrophils during infection or inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.